GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » Cyclically Adjusted Revenue per Share

Aevi Genomic Medicine (Aevi Genomic Medicine) Cyclically Adjusted Revenue per Share : $0.00 (As of Sep. 2019)


View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aevi Genomic Medicine's adjusted revenue per share for the three months ended in Sep. 2019 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2019.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-27), Aevi Genomic Medicine's current stock price is $0.1659. Aevi Genomic Medicine's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2019 was $0.00. Aevi Genomic Medicine's Cyclically Adjusted PS Ratio of today is .


Aevi Genomic Medicine Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Aevi Genomic Medicine's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine Cyclically Adjusted Revenue per Share Chart

Aevi Genomic Medicine Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aevi Genomic Medicine Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aevi Genomic Medicine's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Aevi Genomic Medicine's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aevi Genomic Medicine's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aevi Genomic Medicine's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aevi Genomic Medicine's Cyclically Adjusted PS Ratio falls into.



Aevi Genomic Medicine Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aevi Genomic Medicine's adjusted Revenue per Share data for the three months ended in Sep. 2019 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=0/108.3294*108.3294
=0.000

Current CPI (Sep. 2019) = 108.3294.

Aevi Genomic Medicine Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200912 0.000 91.111 0.000
201003 0.000 91.821 0.000
201006 0.000 91.962 0.000
201009 0.000 92.162 0.000
201012 0.000 92.474 0.000
201103 0.000 94.283 0.000
201106 0.000 95.235 0.000
201109 0.000 95.727 0.000
201112 0.000 95.213 0.000
201203 0.000 96.783 0.000
201206 0.000 96.819 0.000
201209 0.000 97.633 0.000
201212 0.000 96.871 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Aevi Genomic Medicine  (NAS:GNMX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aevi Genomic Medicine Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Industry
Traded in Other Exchanges
N/A
Address
435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.
Executives
Michael F Cola director, officer: Chief Executive Officer 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil officer: Chief Scientific Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca 10 percent owner 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper officer: CFO & Corporate Secretary C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz director C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum officer: Chief Legal Officer C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman officer: Chief Financial Officer 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio officer: Chief Operating Officer 435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087